Log In Sign up
The largest database of trusted experimental protocols

Taqman hiv 1 test

Manufactured by Roche
Visit Supplier

The TaqMan HIV-1 test is a real-time PCR assay designed for the quantitative detection of HIV-1 RNA in human plasma. It provides accurate and reliable viral load measurements to monitor HIV-1 infection.

Automatically generated - may contain errors

Lab products found in correlation

Amplicor hiv 1 monitor test, by Roche (2 mentions) Cobas amplicor hiv 1 monitor test, by Roche (1 mentions) Amplicor hiv 1 monitor ultrasensitive test, by Roche (1 mentions)

Close spelling variants of this product

COBAS AmpliPrep/COBAS TaqMan HIV-1 Test (68 citations) Cobas Ampliprep/Cobas Taqman HIV-1 Test, Version 2.0 (14 citations) COBAS TaqMan HIV-1 Test (13 citations) AmpliPrep/COBAS® TaqMan®HIV-1 Test (12 citations) COBAS TaqMan HIV-1 test V2.0 (11 citations) COBAS TaqMan HIV-1 Test Version 2.0 (8 citations) Roche COBAS AmpliPrep/COBAS TaqMan HIV-1 Test v2.0 (4 citations) Cobas Ampliprep/Cobas Taqman HIV-1 Test, Version (3 citations) AmpliPrep/Cobas TaqMan HIV-1 test v 2.0 (3 citations) COBAS® AmpliPrep/COBAS® TaqMan® HIV‐1 Test v2.0 kit (3 citations)

4 protocols using taqman hiv 1 test

1

Virologic Outcomes After ART Failure

Check if the same lab product or an alternative is used in the 5 most similar protocols
The primary outcome was ART failure within 12 months of surgery, defined by the US Department of Health and Human Services (DHHS) as failure to suppress or sustain an HIV viral load to less than 200 copies/mL [17 ]. Due to the long length of the study period, various assays were used to detect viral load including the Roche COBAS Ampliprep/COBAS TaqMan HIV-1 test with a lower limit of detection of 20 copies/mL most recently, branched DNA tests with a lower limit of detection of 75 copies/mL, and others. Secondary outcomes included characterizing those who suffered virologic failure compared to those with sustained virologic suppression in terms of metabolic parameters, CD4+ count, acid suppression use, postoperative complications, ART regimen changes, adherence, and resistance.
Kaip E.A., Nguyen N.Y, & Cocohoba J.M. (2022). Antiretroviral Therapy Efficacy Post-Bariatric Weight Loss Surgery: A Case Series of Persons Living with Human Immunodeficiency Virus. Obesity Surgery, 32(5), 1523-1530.
+ Open protocol
+ Expand
2

Long-term Virologic Outcomes in HIV

Check if the same lab product or an alternative is used in the 5 most similar protocols
The primary efficacy endpoint represented the proportion of patients with confirmed and sustained virologic response (VR [VL of <50 copies/mL]) according to the time to loss of VR (TLOVR) algorithm at week 24 and was presented in a previous publication (10 ). The secondary efficacy endpoints at week 240 were the proportion of patients with VR using the FDA Snapshot approach (26 ), TLOVR (27 ), and change in CD4+ cell count (absolute and percentage) from baseline up to week 240.
Plasma VL was assessed at prespecified time points using the Roche Cobas Amplicor HIV-1 Monitor test, version 1.5 (lower limit of quantification [LLOQ], 50 copies/mL [until the end of 2012]), or the Roche Cobas TaqMan HIV-1 test, version 2.0 (LLOQ, 20 copies/mL [after 2012]).
Lombaard J., Ssali F., Thanyawee P., Fourie J., Vanveggel S., Linthicum C., Van Eygen V, & Van Solingen-Ristea R. (2022). Phase 2 Open-Label Study of Long-Term Safety, Tolerability, and Antiviral Activity of Rilpivirine in Antiretroviral-Naive Adolescents Living with HIV-1. Antimicrobial Agents and Chemotherapy, 66(2), e00916-21.
+ Open protocol
+ Expand
3

Assessing Immune Status in HIV Patients

Check if the same lab product or an alternative is used in the 5 most similar protocols
The percentage of lymphocytes that were CD4+ T cells was determined by flow cytometry. HIV viral load was determined via either the COBAS TaqMan HIV-1 Test, version 2.0, or Roche Amplicor HIV-1 MONITOR Test, version 1.5. Both tests quantify HIV-1 RNA based on in vitro amplification of the highly conserved HIV-1 gag gene. Nadir CD4+ T cell count was obtained either by self-reports or, for those who seroconverted during the course of the study, their lowest CtaD4+ count according to study records. Duration of infection was calculated based on self-reported year of conversion or study records if they seroconverted while in the MACS.
Quach A., Horvath S., Nemanim N., Vatakis D., Witt M.D., Miller E.N., Detels R., Langfelder P., Shapshak P., Singer E.J, & Levine A.J. (2018). No reliable gene expression biomarkers of current or impending neurocognitive impairment in peripheral blood monocytes of persons living with HIV. Journal of neurovirology, 24(3), 350-361.
+ Open protocol
+ Expand
4

Measuring HIV Viral Load Suppression

Check if the same lab product or an alternative is used in the 5 most similar protocols
One of three assays were used for measuring VL: Amplicor HIV-1 monitor test (Roche Diagnostics, lower limit of detection [LLD]=400 copies/mL, Pre-2002: 11%); Amplicor HIV-1 monitor ultrasensitive test (Roche Diagnostics, LLD=50, 2002–2010: 64%); TaqMan HIV-1 test (Roche Diagnostics, LLD=20, 2011–2015: 25%). VLs below the LLD were set to 300, 40 and 10 copies/mL, respectively, per MACS operating protocols. Longitudinal VL data were measured at semiannual study visits. For cART-prevalent individuals, the last VLs within 6 months before cART initiation were abstracted from medical records.
Viral suppression was defined as consistent VL measurements below the LLD allowing one blip <400 copies/mL. Using this definition, proportions of virally suppressed participants were calculated at single time-points (the last pre-cART, first post-cART and most recent visits) and over various time windows (as explained below).
WANG R., HABERLEN S.A., PALELLA FJ J.R., MUGAVERO M.J., MARGOLICK J.B., MACATANGAY B.J., MARTÍNEZ-MAZA O., JACOBSON L.P, & ABRAHAM A.G. (2018). Viremia copy-years and mortality among cART-initiating HIV-positive individuals: how much viral load history is enough?. AIDS (London, England), 32(17), 2547-2556.
+ Open protocol
+ Expand

About PubCompare

Our mission is to provide scientists with the largest repository of trustworthy protocols and intelligent analytical tools, thereby offering them extensive information to design robust protocols aimed at minimizing the risk of failures.

We believe that the most crucial aspect is to grant scientists access to a wide range of reliable sources and new useful tools that surpass human capabilities.

However, we trust in allowing scientists to determine how to construct their own protocols based on this information, as they are the experts in their field.

Ready to get started?

Sign up for free.
Registration takes 20 seconds.
Available from any computer
No download required

Sign up now

Revolutionizing how scientists
search and build protocols!